AU3359693A - A major histocompatibility complex class II antigen in a vaccine against an immunodeficiency virus - Google Patents
A major histocompatibility complex class II antigen in a vaccine against an immunodeficiency virusInfo
- Publication number
- AU3359693A AU3359693A AU33596/93A AU3359693A AU3359693A AU 3359693 A AU3359693 A AU 3359693A AU 33596/93 A AU33596/93 A AU 33596/93A AU 3359693 A AU3359693 A AU 3359693A AU 3359693 A AU3359693 A AU 3359693A
- Authority
- AU
- Australia
- Prior art keywords
- antigen
- cells
- virus
- animals
- immunodeficiency virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000700605 Viruses Species 0.000 title claims description 46
- 229960005486 vaccine Drugs 0.000 title claims description 34
- 239000000427 antigen Substances 0.000 title claims description 26
- 108091007433 antigens Proteins 0.000 title claims description 26
- 102000036639 antigens Human genes 0.000 title claims description 26
- 206010061598 Immunodeficiency Diseases 0.000 title claims description 13
- 208000029462 Immunodeficiency disease Diseases 0.000 title claims description 13
- 230000007813 immunodeficiency Effects 0.000 title claims description 13
- 102000043131 MHC class II family Human genes 0.000 title description 5
- 108091054438 MHC class II family Proteins 0.000 title description 5
- 241001465754 Metazoa Species 0.000 claims description 45
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 14
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 2
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 55
- 241000713311 Simian immunodeficiency virus Species 0.000 description 24
- 229940031551 inactivated vaccine Drugs 0.000 description 11
- 241000282693 Cercopithecidae Species 0.000 description 9
- 241000282567 Macaca fascicularis Species 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 241000282553 Macaca Species 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 101710091045 Envelope protein Proteins 0.000 description 7
- 101710188315 Protein X Proteins 0.000 description 7
- 102100021696 Syncytin-1 Human genes 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000004989 spleen cell Anatomy 0.000 description 5
- 241000282560 Macaca mulatta Species 0.000 description 4
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000001566 pro-viral effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 3
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 3
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 2
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940124718 AIDS vaccine Drugs 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108700027479 Syntex adjuvant formulation Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229910001679 gibbsite Inorganic materials 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- -1 prop lene glycol Chemical compound 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 208000021160 simian immunodeficiency virus infection Diseases 0.000 description 1
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
A MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II ANTIGEN IN A VACCINE AGAINST AN IMMUNODEFICIENCY VIRUS
This invention relates to vaccines against immunodeficiency viruses.
There has been pessimism about the prospects for a successful vaccine against AIDS. The obstacles have often appeared to be insuperable. An effective vaccine must prevent infection by a virus which destroys CD4* cells, which can integrate into the host DNA and which exhibits rapid antigenic variation. Furthermore, protection must be effective at mucosal surfaces, the primary site of entry, and against both cell-free and cell-associated virus. The simian immunodeficiency virus (SIV)-macaque model, developed in the USA1,2, was adopted by the United Kingdom MRC AIDS Directed Programme with the primary objective of establishing that vaccination was feasible and that these obstacles to success could be overcome.
We have now demonstrated that a major histocompatibiiity complex (MHC) class II antigen can protect animals in the SIV-macaque model. Accordingly, the invention provides a class II antigen for use in a method of treatment of the human or animal body by therapy, in particular for use as a vaccine against an immunodeficiency virus.
The invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, a MHC class II antigen. The invention further provides use of a MHC class II antigen in the manufacture of a medicament for use as a vaccine against an immunodeficiency virus.
The antigen is preferably a human class II antigen. The antigen may therefore be a HLA-DP, HLA-DQ or HLA-DR antigen such as the HLA-DR4 antigen. These are known antigens and can be obtained in purified form. They may be prepared as recombinant proteins.
Alternatively, the class II antigen may be given presented by transfected cells, i.e. by cells transfected with a gene encoding the antigen and which consequently express the antigen. Transfected cells which may be administered to a human may be transfected cells of a human diploid cell line. Such cell lines have been tested for safety for the purpose of
human vaccine manufacture. An appropriate cell line is the MRC5 cell line.
Allogeneic lymphocytes which present a class II antigen may be administered to a patient. The lymphocytes may be given as live cells, for example as a blood transfusion. Alternatively they may also be given as fixed or inactivated cells. The lymphocytes may be ones in which the expression of the class II antigen has been enhanced, for example by stimulation with a mitogen or gamma-interferon. The antigen may be used to vaccinate a host against an immunodeficiency virus. The host may be a human or animal but typically it will be wished to vaccinate a human against a human immunodeficiency virus (HIV) . That virus may be HIV-1 or H V-2. A prophylactic treatment for disease states attributable to infection by an immunodeficiency virus can therefore be provided. The class II antigen may in particular act as an AIDS vaccine.
An effective amount of the antigen is administered to a host it is wished to vaccinate. The antigen in whichever form, can be given parenterally, for example subcutaneously, intramuscularly or intravenously. The amount of antigen per dose depends on a variety of factors such as the age and the condition of the subject involved. A parenteral dose typically consists of from 20μg to 1 mg of antigen, for example from 50 to 500 μg of antigen. A number of doses may be given, for example from 2 to 4 doses over a period of up to six months. Each dose may be given one or two months apart.
An agent for use as a vaccine against an immunodeficiency virus is therefore provided. A pharmaceutical composition also comprising a pharmaceutically acceptable carrier or diluent can be formulated. The composition is thus sterile and pyrogen-free. The composition may also comprise an adjuvant such as Al(OH)3 or saponin.
Compositions for intramuscular or subcutaneous injections may contain together with the antigen a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols e.g. prop lene glycol, and if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusions may contain
as carrier, for example, sterile water or preferably they may be in the form of sterile aqueous isotonic saline solutions.
The MHC class II antigens can be safely used by virtue of their negligible toxicity. The following Examples illustrate the invention.
Example 1 Inactivated Vaccines
In initial experiments relatively crude, inactivated vaccines were deliberately used (Table 1) . The virus infected C8166 cells (Virology, 129. 51-64, 1983 in which the cells are called C63/CR11-2 cells) or partially purified virus, inactivated either by aldehydes or 0-propiolactone, were given to groups of three or four cynomolgus macaques. Four doses of vaccine were administered with a rest period of at least six months between the third and final doses. Three different adjuvants were used, either Quil-a (a purified saponin) , SAF-1 (Syntex emulsion containing threonyl muramyl di-peptide) or Freund's adjuvant. Each group of vaccinated animals, together with a group of unvaccinated controls, was challenged intravenously with 10MID50 of the 32H isolate of SIVmac251, two weeks after the final dose of vaccine. All control animals became infected. Virus was repeatedly isolated and proviral DNA detected in peripheral blood lymphocytes after amplification by polymerase chain reaction. Furthermore significant antibody responses to SIV were detected. In contrast there was no evidence of virus infection to any of the vaccinated animals by any of these criteria. These experiments with inactivated virus vaccines have been extended to show that the immunization schedule can be reduced to three doses given at monthly intervals. The duration of protection was assessed by re-challenging animals four to six months after the final dose of vaccine. Five of eight macaques were protected. These results together with other published data2,3'*'5 demonstrate that inactivated vaccines induce a powerful protection against SIV infection in macaques and that this protection is still detectable at least 6 months after the completion of vaccination. Cross-Protection
The breadth of protection induced by SIV vaccines
was investigated by vaccinating eight rhesus and eight cynomolgus macaques with formalin inactivated SIV using SAF-1 as adjuvant. Two weeks after the fourth dose of vaccine, four rhesus and four cynomolgus monkeys were challenged with the homologous virus. All eight animals were completely protected against infection. The four remaining rhesus monkeys were challenged with 10MID50 of SlV^^g^ (kindly supplied by Dr. M. Murphy-Corb) . These animals also resisted infection. The remaining four cynomolgus macaques were challenged with 10MID50 of HIV-2SBL6669 (kindly supplied by Drs. P. Putkonen and G.
Biberfield) . These animals all became infected. Analysis of the viruses involved in these cross-protection experiments revealed that SIVmac251 and SIVdelta share 83% identity in the amino acid sequences of their envelope proteins. In contrast, SIVmac251 and HIV-2SBL are only 73% identical in the envelope protein. The antigenic diversity of these viruses was established using a panel of 30 monoclonal antibodies made against the envelope protein of SIVmac251. Although all of these antibodies reacted with the vaccine virus in an ELISA assay, 11 failed to react with SIVdelta and 20 failed to reach with HIV-2SBL. These results indicate that inactivated vaccine prepared from SIVmac completely protects animals against challenge with the antigenically distinct strain of SIV^,^, but that this cross-protection does not extend to the more distantly related HIV-2 virus. Thus, the antigenic variability of immunodeficiency viruses may not be as big an obstacle to successful vaccination as was originally feared. However, this conclusion may require reinterpretation in the light of anti- cell responses discussed below. Mucosal Immunity
The problem of inducing protection at a mucosal surface was investigated using the intrarectal route of challenge. The standard challenge virus pool of the 32H isolate of SIVmac251, which had been used in all the previous intravenous challenges, was first titrated in rhesus macaques using the intrarectal route. One thousand times more viruses was required to infect monkeys by this route, but the subsequent course of infection was essentially indistinguishable from that following intravenous inoculation.
Four rhesus macaques were then vaccinated subcutaneously with formalin-inactivated SIV using SAF-1 as adjuvant. Two weeks after the fifth dose of vaccine the animals were challenged intrarectally with 10MID50 based on the intrarectal titration. Four unvaccinated control animals challenged at the same time all became infected. In contrast, all four of the vaccinated animals have remained uninfected over a period of at least six months. This experiment indicates that immunity can be induced against challenge via a mucosal surface. Challenge with Cell-Associated Virus
A cell associated challenge virus stock was prepared from the spleen of a cynomolgus macaque J82 which had been infected with the 32H isolate of SIVmac251 ten weeks previously. Aliquots of the cells were cryopreserved and then titrated in vitro by co-cultivation with C8166 cells (Table 2) . The infectivity titres of the cells and their supernatant fluid were log10 4.5 and 2.5 respectively. Thus 99% of the infectivity was cell-associated and one ID50 was equivalent to 72 viable cells. Subsequent titration of the spleen cells in vivo in monkeys gave an end-point of log10 3.0 with one ID50 being equivalent to 2,300 cells. Having prepared and titrated intravenously an appropriate cell-associated virus challenge, four cynomolus macaques were selected which had previously been vaccinated subcutaneously with inactivated SIV and shown to be protected against intravenous cell-free virus challenge. These animals which had remained free of virus for twelve months following initial challenge were revaccinated and two weeks later challenged intravenously with cell-associated virus (Table 3). The four vaccinated animals, together with four unvaccinated controls, all became infected. Virus and proviral DNA were detected repeatedly in the peripheral blood lymphocytes. Thus a vaccine which had protected against intravenous challenge with cell-free virus grown in a human T- cell line failed to protect against SIV infected simian spleen cells.
Recombinant Vaccines
The specific compounds within the inactivated vaccine which were responsible for the protection were next sought by immunization with a variety of recombinant proteins
derived from SIV genes. Groups of four monkeys were immunised either with p27 expressed on yeast virus-like particles and combined with aluminium hydroxide, or with purified gpl60 derived from a recombinant vaccinia virus, or gpl30 expressed in CHO cells, or gpl40 expressed by baculovirus. Each of the envelope proteins was administered with the Syntex adjuvant formulation. Vaccines were given in four doses and the animals were challenged with 10MID50 of SIV two weeks after the final dose, together with groups of four unvaccinated control animals. All of these monkeys became infected except one which was vaccinated with the baculovirus derived gpl40. Thus although recombinant proteins were able to induce high titres of antibody against SIV envelope, they were not able to protect animals against intravenous challenge. Immune Correlates of Protection
The immune responses which correlated with protection were analysed by measuring antibody titres in sera taken on the day of challenge from 55 vaccinated macaques used in these studies. Forty three animals had received inactivated vaccines and 12 a recombinant envelope protein (Table 4) .
Neutralising antibodies were measured against SIVmac251 grown as a persistent infection in HUT-78 cells. The mean titre of neutralizing antibody in the group of 32 macaques which received inactivated vaccine and were protected was log10 2.0 ± 0.5. The same mean value was found in the group of 11 animals which were unprotected. Furthermore the 11 animals vaccinated with recombinant envelope proteins and unprotected, had a higher mean titre of log10 2.9 ± 0.5. Thus there was no clear correlation between titres of neutralising antibodies and protection in these animals. Titration of these sera against recombinant envelope gpl40 by ELISA also failed to show any correlation with protection. Similarly, although these vaccines induced strong T-helper cell proliferation responses to SIV, and in some cases MHC class-II restricted cytotoxic cells, there was no obvious correlation between the cellular responses to SIV and protection. Our failure to find any correlation between the powerful protection we have observed following vaccination and any of the immune responses which we had measured was disturbing. However, it is possible that the
immunological assays we used were inappropriate. Responses to Cell Components
At this point results of a further vaccine experiment began to emerge which offered explanation for our observations (Table 5) . This experiment was originally designed to examine if the two doses of vaccine were sufficient to protect against intravenous challenge with cell-fee virus. Four cynomolgus macaques were vaccinated with SIV-infected C8166 cells using Quil-A as adjuvant at weeks 0 and 4. A control group of four animals were similarly vaccinated but with uninfected C8166 cells. Both groups were challenged with 10MID50 of virus two weeks after the second dose of vaccine. One of the four animals vaccinated with SIV-infected cells became infected but, surprisingly, only two of the four vaccinated with uninfected cells became infected. In order to confirm these surprising results the protected animals were further vaccinated at week 26 and re-challenged two weeks later together with four naive control macaques. Partial protection was again observed in the animals immunised with uninfected C8166 cells, whereas all four unvaccinated control animals became infected. Antibodies to the cellular component of these vaccines were measured by ELISA using a detergent lysate of C8166 cells as antigen (Table 6) . The mean titre of antibody in the eight protected animals was log10 3.5 and in the five unprotected animals log10 2.4. The difference between these two groups was highly significant. Analysis of anti-cell antibody levels in all the animals which had received inactivated vaccines showed a similar difference between protected and unprotected animals. Thus there was a statistical correlation between the titre of antibody to C8166 cells and protection in these animals. Conclusions
These studies demonstrate that at least 3 different inactivated vaccines protect against homologous cell-free SIV. The protection induced is potent since neither virus nor proviral DNA can be detected in the vaccinated animals over prolonged periods following challenge. Five different adjuvants and a variety of immunization procedures are effective. The inactivated vaccines protect against
heterologous challenge with SIVdelta but not against HIV-2. The immunity against challenge is reduced but still detectable at four and eight months post-vaccination. Parenteral vaccination with inactivated virus protects against intrarectal challenge with cell-free virus, but not against intravenous challenge with SIV-infected simian spleen cells. Three different preparations of SIV envelope protein were shown to be highly immunogenic, but failed to protect against live intravenous challenge. The protection observed failed to correlate with any of the immune reactions to SIV which were measured.
However there was a correlation between protection and levels of antibody to C8166 cells. These results suggest that the protection observed may be mediated at least in part, by immune responses to cellular components present within the inactivated vaccines.
TABLE 1 SUCCESSFUL INACTIVATED SIV VACCINES
ANIMALS WERE CHALLENGED INTRAVENOUSLY 2 WEEKS AFTER VACCINATION WITH 10 MIDS0.
* NUMBER INFECTED/NUMBER CHALLENGED
TABLE 2 TITRATION OF CELL ASSOCIATED VIRUS
* SPLEEN CELLS FROM SIV-INFECTED CYNO J82
TABLE 3 CHALLENGE WITH CELL-ASSOCIATED SIV
* DATE OF INTRAVENOUS CHALLENGE WITH CELL-FREE VIRUS.
+ ALL ANIMALS CHALLENGED INTRAVENOUSLY WITH INFECTED SPLEEN CELLS TWO WEEKS FTER LAST DOSE OF VACCINE.
TABLE 4 NEUTRALIZING ANTIBODIES AND PROTECTION
* TITRE EXPRESSED AS LOG 10
TABLE 5 VACCINATION UIITH C8166 CELLS (TEIAL 22)
* No INFECT/NO CHALLENGED
TABLE 6 CORRELATION OF PROTECTION WITH ANTIBODY TO C8166 CELL
* TITRES EXPRESSED AS LOG 10
- 15 -
Example 2
To confirm the protection influenced by uninfected human T cells, a second experiment was initiated (Table 6) . Groups of 4 cynomolgus macaques were vaccinated with either C8166 cells (a human T cell line) or RK-13 cells (rabbit kidney fibroblasts) . A third group acted as naive controls. The cells were gently fixed with 0.075% glutaraidehyde and combined with Quil A (a purified saponin) as adjuvant. Each dose comprised 2 x 10s cells and lOμg of Quil A. The vaccines were administered subcutaneously at 0, 4, 8 and 16 weeks. Two weeks after the final dose of vaccine all 12 macaques were challenged with 10 monkey infectious doses (MID50) of simian immunodeficiency virus (SIVmac32H) which had been grown in C8166 cells. Virus and proviral DNA was detected in all the control animals and those vaccinated with RK-13 cells but in only two of the four given C8166 cells (Table 2.1).
To confirm and extend this observation the two protected animals were given another dose of C8166 cells at 30 weeks. Two weeks later they, and four naive controls, were challenged with 10 MID50 of an antigenically distinct virus, SIVsm3 which had been grown in human peripheral blood mononuclear cells (PBMC) from at least two donors. The controls were all infected but the two vaccinates remained protected. Finally, the protected animals were vaccinated again at 44 weeks and challenged, together with four controls, with 10 MID50 of SIVmac251 grown in simian PBMC. All the animals became infected.
This experiment confirms that uninfected human T cells protect against at least two antigenically distinct strains of SIV grown in human T cells which need not be identical with the cells used as the vaccine. This protection did not extend to SIV grown in simian cells.
Table 6 : Uninfected Cell Vaccines
+ No. monkeys infected/No. monkeys challenged
Example 3 The major antigens present on the surface of allogeneic or xenogeneic T cells are the major histocompatibiiity antigens (MHC) class I and class II. To determine if these were responsible for the protection observed groups of four cynomolgus macaques were immunised with either a) normal mouse fibroblasts (L cells) , b) L cells (8024 line) transfected with the human genes for MHC class I (HLA B7 + βz microglobulin) or c) L cells (8115 line) transfected with the human genes for MHC class II (HLA-DR4) . By fluorescent antibody staining, over 90% of 8024 and 8115 cells were expressing class I or class II antigen respectively. The cells were gently fixed in 0.075% glutaraldehyde and combined with lOμg of Quil A as adjuvant (Table 7) . Animals were given 2 x 106 cells subcutaneously on four occasions at 0,4,8 and 16 weeks. Two weeks after the last dose, all twelve animals were challenged intravenously with 10 MID50 of SIVmac32H grown in C8166 cells. All the animals in groups a) and b) became infected but only two of four given cells expressing class II.
This result demonstrates that human MHC class II, namely HLA-DR4, can protect animals against SIV grown in human T cells.
Table 7; MHC Class I or Class II Vaccines
No. monkeys infected/No. monkeys challenged with SIVmac32H.
References 1. Desrosiers RC, Ringler DJ. Use of simian immunodeficiency viruses for AIDS research. Int
Virol 3_0, 301-312 (1989).
Desrosiers RC, Wyand MS, Kodama T et al. Vaccine protection against SIV infection. Proc Natl Acad
Sci, New York, 86/ 6353-57 (1989).
Murphy-Corb M, Martin LN, Davison-Fairburn B et al.
A formalin-inactivated whole simian immunodeficiency virus vaccine confers protection in macaques.
Science 246. 1293-97 (1989).
Stott EJ, Chan WL, Mills KHG et al. Preliminary
Report: Protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected cell vaccine. Lancet 336, 1538-41 (1990) .
5. Carlson JR, McGraw TP, Keddie E et al. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum
Retro 6, 1239-46 (1990). 6. Stott EJ, Kitchin PA, Page M et aJL. Anti-cell antibody in macaques. Nature 353. 393 (1991).
Claims (10)
- I. A major histocompatibiiity complex class II antigen for use in a method for treatment of the human or animal body by therapy.
- 2. An antigen according to claim 1 for use as a vaccine against an immunodeficiency virus.
- 3. An antigen according to claim 2, wherein the virus is human immunodeficiency virus (HIV) .
- 4. An antigen according to claim 3, wherein the virus is HIV-1.
- 5. An antigen according to claim 3, wherein the virus is HIV-2.
- 6. An antigen according to any of the preceding claims, which is a human class II antigen.
- 7. An antigen according to claim 6, which is aHLA-DP, HLA-DQ or HLA-DR antigen.
- 8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, a major histocompatibiiity complex class II antigen.
- 9. Use of a major histocompatibiiity complex class II antigen in the manufacture of a medicament for use as a vaccine against an immunodeficiency virus.
- 10. A method of vaccinating a host against an immunodeficiency virus, which method comprising administering to the host an effective amount of a major histocompatibiiity complex class II antigen.II. An agent useful as a vaccine against an immunodeficiency virus, which agent comprises a major histocompatibiiity complex class II antigen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9201023 | 1992-01-17 | ||
GB929201023A GB9201023D0 (en) | 1992-01-17 | 1992-01-17 | Vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3359693A true AU3359693A (en) | 1993-08-03 |
Family
ID=10708778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU33596/93A Abandoned AU3359693A (en) | 1992-01-17 | 1993-01-18 | A major histocompatibility complex class II antigen in a vaccine against an immunodeficiency virus |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0623147A1 (en) |
JP (1) | JPH07505613A (en) |
AU (1) | AU3359693A (en) |
CA (1) | CA2128211A1 (en) |
GB (1) | GB9201023D0 (en) |
WO (1) | WO1993014126A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1274592B (en) * | 1994-08-05 | 1997-07-18 | Angela Turiano | PHARMACEUTICAL COMPOSITION FOR CANCER THERAPY CONTAINING XENOANTIGENS |
US6168787B1 (en) * | 1995-04-24 | 2001-01-02 | John Wayne Cancer Institute | Pluripotent vaccine against enveloped viruses |
FR2735984B1 (en) * | 1995-06-30 | 1997-09-19 | Inst Nat Sante Rech Med | VACCINE AGAINST INFECTIOUS AGENTS HAVING AN INTRACELLULAR PHASE, COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS, ANTIBODIES AND DIAGNOSTIC METHOD |
WO1997036601A1 (en) * | 1996-04-03 | 1997-10-09 | Anergen, Inc. | Cyclic peptide vaccines for treatment and prevention of diabetes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2591227B1 (en) * | 1985-12-06 | 1988-11-10 | Pasteur Institut | PEPTIDES CAPABLE OF INHIBITING INTERACTIONS BETWEEN LAV VIRUSES AND T4 LYMPHOCYTES, DERIVATIVES THEREOF AND THEIR APPLICATIONS |
-
1992
- 1992-01-17 GB GB929201023A patent/GB9201023D0/en active Pending
-
1993
- 1993-01-18 JP JP5512301A patent/JPH07505613A/en active Pending
- 1993-01-18 AU AU33596/93A patent/AU3359693A/en not_active Abandoned
- 1993-01-18 WO PCT/GB1993/000102 patent/WO1993014126A1/en not_active Application Discontinuation
- 1993-01-18 EP EP93902402A patent/EP0623147A1/en not_active Withdrawn
- 1993-01-18 CA CA002128211A patent/CA2128211A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GB9201023D0 (en) | 1992-03-11 |
CA2128211A1 (en) | 1993-07-22 |
EP0623147A1 (en) | 1994-11-09 |
JPH07505613A (en) | 1995-06-22 |
WO1993014126A1 (en) | 1993-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Almond et al. | Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells | |
US6265539B1 (en) | Prophylaxis and therapy of acquired immunodeficiency syndrome | |
US7052699B2 (en) | Immunogenic composition | |
US8003113B2 (en) | DNA vaccine compositions and methods of use | |
QUESADA-ROLANDER et al. | Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope | |
CA2246359A1 (en) | Methods and compositions for protective and therapeutic genetic immunization | |
US7847085B2 (en) | Recombinant HIV-1 gp120 immunogen with three different V3 loops from viruses of different clades | |
EP1038001B1 (en) | Constitutive expression of non-infectious hiv-like particles | |
Notka et al. | Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies | |
GARDNER | Vaccination against SIV infection and disease | |
Mills et al. | Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28‐derived recombinant env and gag proteins | |
Wagner et al. | Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques | |
WO1994017825A1 (en) | Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use | |
US8785411B2 (en) | HIV DNA vaccine methods of use | |
Finerty et al. | Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge | |
AU3359693A (en) | A major histocompatibility complex class II antigen in a vaccine against an immunodeficiency virus | |
Stott | Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines | |
EP0472706B1 (en) | Induction of protection against viral infection | |
EP0328390B1 (en) | Peptide treatment of refractory infectious diseases | |
Cole et al. | A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys | |
Mills et al. | Immunisation of macaques with SIV env recombinants: specificity of T cell and antibody responses and evaluation of protective efficacy | |
Adams et al. | Use of new vectors for the development of vaccines | |
Smith et al. | Preparation and induction of immune responses by a DNA AIDS vaccine | |
Chege | Pre-clinical assessment of novel candidate HIV-1 vaccines using the Chacma baboon | |
ZA200603044B (en) | DNA vaccine compositions and methods of use |